BioPharmSignal logoBioPharmSignal

Biotech News

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

Barinthus Biotherapeutics (BRNS)Barinthus BiotherapeuticsCompany update

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease.

Open original release

Related news

FATEFate Therapeutics2026-05-21 12:30 EST

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

KYMRKymera2026-06-08 11:00 EST

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

RLAYRelay Therapeutics2026-05-19 10:00 EST

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

KYMRKymera2026-05-15 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

FATEFate Therapeutics2026-05-13 12:30 EST

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

REGNRegeneron Pharmaceuticals2026-06-04 11:00 EST

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

ELVNEnliven Therapeutics2026-06-03 20:05 EST

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

NRIXNurix Therapeutics2026-05-13 11:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conferences

View all latest news

Barinthus Biotherapeutics

Barinthus Biotherapeutics is an immunotherapy company focused on vaccines and T-cell therapies for infectious disease and oncology. Its story is built around immune-based approaches to both prevention and treatment.

Recent company news

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2026-03-13 12:00 EST

Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2025-12-10 13:00 EST

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

BRNSBarinthus Biotherapeutics2025-11-07 12:30 EST

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2025-09-30 12:01 EST

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

Stock data

Close
0.60 USD
Market cap
26.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States